# Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care

> **NCT05205928** · PHASE2,PHASE3 · COMPLETED · sponsor: **McGill University Health Centre/Research Institute of the McGill University Health Centre** · enrollment: 28 (actual)

## Conditions studied

- Type 1 Diabetes
- Diabetes Mellitus, Type 1

## Interventions

- **DRUG:** Outpatient therapy: 11 weeks of drug therapy with usual treatment + 4 weeks of closed-loop therapy

## Key facts

- **NCT ID:** NCT05205928
- **Lead sponsor:** McGill University Health Centre/Research Institute of the McGill University Health Centre
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-10-02
- **Primary completion:** 2024-04-15
- **Final completion:** 2024-06-30
- **Target enrollment:** 28 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05205928

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05205928, "Weekly Subcutaneous Semaglutide as Adjunct to Closed-loop Therapy in Type 1 Diabetes Care". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT05205928. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*